7.09
-0.16 (-2.21%)
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Jade Biosciences, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.10 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Allostery Investments Lp | 31 Dec 2024 | 24,304 |
| Julat 52 Minggu | ||
| Median | 17.00 (139.77%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wedbush | 15 May 2025 | 17.00 (139.77%) | Beli | 7.40 |
| 07 May 2025 | 17.00 (139.77%) | Beli | 9.26 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| FROHLICH TOM | 7.35 | - | 6,000 | 44,070 |
| Jumlah Keseluruhan Kuantiti Bersih | 6,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 44,070 | |||
| Purata Pembelian Keseluruhan ($) | 7.35 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| FROHLICH TOM | Pegawai | 16 May 2025 | Beli (+) | 6,000 | 7.35 | 44,070 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 May 2025 | Pengumuman | Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 13 May 2025 | Pengumuman | Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference |
| 21 Apr 2025 | Pengumuman | Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals |
| 09 Apr 2025 | Pengumuman | Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences |
| 07 Apr 2025 | Pengumuman | Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |